Medication info
Dimantine Tablet 20 mg (Memantine Hydrochloride)

Dimantine Tablet 20 mg (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202203939 · Approved 2022.10.28 · Insurance code 642004950

Summary

Main use
Treatment of moderate to severe Alzheimer’s disease
Who takes it
Adults
Adult dose
This drug is administered orally once daily, at the same time each day. If necessary, this drug may be administered twice daily. This drug may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Day 1 to Day 7): Administer 5mg once daily for 7 days. Week 2 (Day 8 to Day 14): Administer 10mg once daily for 7 days. Week 3 (Day 15 to Day 21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients Based on clinical data, the recommended dose in elderly patients 65 years of age and older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated for at least 7 days after administration, the dose may be increased to 20mg once daily according to the standard dose-escalation method. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer’s disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe stage Alzheimer's disease. It helps improve the decline in memory and cognitive function of patients, thereby enhancing their quality of life in daily activities.

How to take

Adult dose

This drug is administered orally once daily, at the same time each day. If necessary, this drug may be administered twice daily. This drug may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Day 1 to Day 7): Administer 5mg once daily for 7 days. Week 2 (Day 8 to Day 14): Administer 10mg once daily for 7 days. Week 3 (Day 15 to Day 21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients Based on clinical data, the recommended dose in elderly patients 65 years of age and older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated for at least 7 days after administration, the dose may be increased to 20mg once daily according to the standard dose-escalation method. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.

Precautions

This medicine should not be used by individuals who are allergic to any of its components. It should also not be administered to patients with severely impaired liver function or significantly decreased kidney function. Since this medication contains lactose, individuals with hereditary disorders that prevent lactose digestion should not take it. Patients with epilepsy or those who have experienced seizures in the past, or individuals predisposed to epilepsy should use this medication with caution. Moreover, simultaneous use with certain medications such as amantadine, ketamine, or dextromethorphan may increase side effects, so it is advisable not to co-administer them. If there are changes in dietary habits that may affect urine acidity or if there are specific kidney disorders, urine status should be monitored carefully. Patients with heart problems or uncontrolled hypertension need to be cautious while using this medication. Taking this medication may result in side effects such as dizziness, headache, constipation, drowsiness, and high blood pressure, and in some patients, hallucinations or psychotic symptoms have been rarely reported. If taken with certain medications, it may interact with them, leading to changes in effectiveness or increased side effects, so it is essential to consult a doctor or pharmacist if taking other medications. Women who are pregnant or may become pregnant should be careful when taking this medication, and breastfeeding women are advised to discontinue breastfeeding while on this medication. It is advisable not to use this medication in children or adolescents under 18 years of age, as safety and efficacy have not been established. In case of overdose, central nervous system and digestive system issues may arise, and immediate medical attention should be sought. This medication can slow down reaction times, so caution should be exercised when driving or operating machinery. Finally, keep this medication out of the reach of children and avoid transferring it to other containers.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity
  • confusion
  • hallucination
  • psychotic reaction
Show 21 more
  • balance disorder
  • gait abnormality
  • seizure
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevation of liver function test values
  • hepatitis
  • fatigue
  • agitation
  • aggression
  • stupor
  • unconsciousness
  • restlessness
  • psychosis
  • visual hallucination
  • convulsion
  • coma
  • double vision

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that allows no air to pass through, at a temperature maintained at room temperature between 1 and 30 degrees Celsius. Storing it this way ensures the stability of the medication's components and allows it to exert its effects properly.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.